Optic neuritis: guidelines.
A major breakthrough in the therapy of demyelinating disease has recently been disclosed by the Optic Neuritis Treatment Trial. Over the past 6 years the trial has accumulated evidence that a high dose of corticosteroids taken to treat patients with an isolated acute attack of optic neuritis reduces the rate at which multiple sclerosis develops over a 2-year period of follow-up. The findings of the trial have had an immediate impact on the neuro-ophthalmic and neurologic community in the USA; therefore, I have focused my review on this important topic.
Wray
S H
SH
Department of Neurology, Massachusetts General Hospital, Boston, USA.
D002985:Clinical Protocols; D018450:Disease Progression; D006801:Humans; D008775:Methylprednisolone / Q000008:administration & dosage / Q000627:therapeutic use*; D009103:Multiple Sclerosis / Q000503:physiopathology; D009902:Optic Neuritis / Q000188:drug therapy* / Q000503:physiopathology; D011239:Prednisolone / Q000008:administration & dosage / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D014786:Vision Disorders / Q000503:physiopathology
D011239:Prednisolone; D008775:Methylprednisolone